Corcept Therapeutics (CORT) Raw Materials (2012 - 2024)

Corcept Therapeutics' (CORT) quarterly Raw Materials came in at $704000.0 in Q1 2024, down 58.22% quarter-over-quarter from $1.7 million in Q4 2020.

Corcept Therapeutics (CORT) Raw Materials (2012 - 2024) Analysis & Trends

Corcept Therapeutics has disclosed Raw Materials across 10 years of filings, most recently posting $704000.0 for Q1 2024.

Raw Materials for Q1 2024 came in at $704000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $704000.0 (changed N/A YoY), and the FY2020 annual result was $1.7 million, up 21.31% from the prior year.
Raw Materials came in at $704000.0 for Q1 2024 at Corcept Therapeutics, down from $1.7 million in the prior quarter.
In the past five years, Raw Materials ranged from a high of $1.7 million in Q4 2020 to a low of $704000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Corcept Therapeutics	8.35 Bn	8.01 Bn	162.02 Mn

Download Data